Effectiveness and safety of reduced dose non-Vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study

BMJ (Online)

Volumn 356, Issue , 2017, Pages

  Nielsen, Peter Brønnum ^a   Skjøth, Flemming ^a,b   Søgaard, Mette ^a,b   Kjældgaard, Jette Nordstrøm ^a,b   Lip, Gregory Y H ^a,c   Larsen, Torben Bjerregaard ^a,b  

^a AALBORG UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DENMARK; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NON VALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PROBABILITY; PROPENSITY SCORE; REGISTER; RISK ASSESSMENT; VERY ELDERLY; COMPARATIVE STUDY; EMBOLISM; INCIDENCE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; DABIGATRAN; DENMARK; EMBOLISM; HUMANS; INCIDENCE; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; WARFARIN;

EID: 85012257350     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j510     Document Type: Article

References (42)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. doi: 10.1016/S0140-6736(13)62343-0.
2. January CT, Wann LS, Alpert JS, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-76. doi:10.1016/j.jacc.2014.03.022.
3. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413. doi:10.1093/europace/eus305.
4. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189. doi:10.1136/bmj.i3189.
5. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73. doi:10.1016/j.jacc.2013.03.020.
6. Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016;115:152-60. doi:10.1160/TH15-03-0247.
7. Gorst-Rasmussen A, Lip GYH, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016;25:1236-44. doi:10.1002/pds.4034.
8. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-507. doi:10.1093/europace/euv309.
9. Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35. doi:10.1056/NEJMoa1105594.
10. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962. doi:10.1093/eurheartj/ehw210.
11. Nielsen PB, Lane DA, Rasmussen LH, Lip GYH, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015;104:418-29. doi:10.1007/s00392-014-0797-9.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. doi:10.7326/0003-4819-146-12-200706190-00007.
13. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. doi:10.1016/S0140-6736(13)62343-0.
14. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449-90. doi:10.2147/CLEP.S91125.
15. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007;28:150-4. doi:10.1159/000102143.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706. doi:10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O.
17. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. doi:10.1378/chest.10-0134.
18. Diener H-C, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2016ehw069. doi:10.1093/eurheartj/ehw069.
19. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. doi:10.1097/00001648-200009000-00011.
20. Stürmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med 2014;275:570-80. doi:10.1111/joim.12197.
21. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388-414. doi:10.1002/sim.5753.
22. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-79. doi:10.1002/sim.6607.
23. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009;51:171-84. doi:10.1002/bimj.200810488.
24. Stürmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf 2006;15:698-709. doi:10.1002/pds.1231.
25. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int 2012;82:270-7. doi:10.1038/ki.2012.65.
26. Schaeffner ES, Ebert N, Delanaye P, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012;157:471-81. doi:10.7326/0003-4819-157-7-201210020-00003.
27. Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. doi:10.1056/NEJMoa1107039.
28. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864-72. doi:10.1093/eurheartj/ehu046.
29. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86. doi:10.1111/bcp.12106.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. doi:10.1056/NEJMoa0905561.
31. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129:961-70. doi:10.1161/CIRCULATIONAHA.113.003628.
32. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. doi:10.1056/NEJMoa1009638.
33. Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25:431-42. doi:10.1681/ASN.2013040361.
34. Vestergaard AS, Skjøth F, Lip GYH, Larsen TB. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study. Stroke 2016;47:979-85. doi:10.1161/STROKEAHA.115.012338.
35. LaHaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014;111:465-73. doi:10.1160/TH13-05-0424.
36. Lane DA, Lip GYH. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014;111:381-3. doi:10.1160/TH14-01-0063.
37. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015;313:1950-62. doi:10.1001/jama.2015.4369.
38. Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ. Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res 2012;21:31-54. doi:10.1177/0962280210386207.
39. Lip GYH, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111:933-42. doi:10.1160/TH13-09-0734.
40. Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016;1:451-60. doi:10.1001/jamacardio.2016.1170.
41. Grams ME, Plantinga LC, Hedgeman E, et al. CDC CKD Surveillance Team. Validation of CKD and related conditions in existing data sets: A systematic review. Am J Kidney Dis 2011;57:44-54. doi:10.1053/j. ajkd.2010.05.013.
42. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011;90:777-90. doi:10.1038/clpt.2011.235.